Sovaldi Among New HCV Drugs In Turkey Reimbursement Pact
This article was originally published in PharmAsia News
Turkey’s public health payer has added three new hepatitis C drugs to the reimbursement list through a special deal with manufacturers, although the price the SGK will be paying to the companies is not being revealed.
You may also be interested in...
As Turkey’s government discloses health care and drug budget plans for 2017, it is becoming clear that controlling the rise in national costs while meeting needs will remain central to policies, prompting the consideration of a variety of approaches.
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.